Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial

Haematologica

Volumn 98, Issue 11, 2013, Pages 1726-1731

  Mounier, Nicolas ^a   El Gnaoui, Taoufik ^b   Tilly, Hervé ^c   Canioni, Danièle ^d   Sebban, Catherine ^e   Casasnovas, René Olivier ^f   Delarue, Richard ^d   Sonet, Anne ^g   Beaussart, Pauline ^b   Petrella, Tony ^f   Castaigne, Sylvie ^h   Bologna, Serge ⁱ   Salles, Gilles ^j   Rahmouni, Alain ^b   Gaulard, Philippe ^b   Haioun, Corinne ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c Centre Bequerel   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e CENTRE LÉON BÉRARD   (France)

^f HÔPITAL DU BOCAGE   (France)

^g UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^h CENTRE HOSPITALIER DE VERSAILLES   (France)

ⁱ CHU NANCY BRABOIS   (France)

^j CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOXORUBICIN; GEMCITABINE; OXALIPLATIN; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CAUSE OF DEATH; CLINICAL ARTICLE; DROWNING; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RECURRENCE; SURVIVAL RATE;

EID: 84886992205     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.090597     Document Type: Article

References (23)

1. El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007; 18(8): 1363-8.
2. Benichou J, Bellissant E, Chastang C. Analysis of phase II clinical trials in haematology and oncology: comparison of the triangular test to the usual methods. Stat Med. 1991; 10(6): 989-90.
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organisation Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn Geneva: World Health Organisation. 2008: 168-70.
4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4): 1244.
5. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990; 8(12): 1935-7.
6. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1): 275-82.
7. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004; 100(12): 2664-70.
8. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. J Clin Oncol. 2012; 30(36): 4462-9.
9. Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, et al. Longterm results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol. 2009; 64(5): 907-16.
10. Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol. 2006; 17 (Suppl 4): iv18-24.
11. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′, 2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999; 44(2): 117-23.
12. Chau I, Webb A, Cunningham D, Hill M, Rao S, Ageli S, et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol. 2001; 115(4): 786-92.
13. Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (RDHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010; 10(4): 262-9.
14. Machover D, Delmas-Marsalet B, Misra SC, Gumus Y, Goldschmidt E, Schilf A, et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol. 2001; 12(10): 1439-43.
15. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004; 103(10): 3684-8.
16. Jermann M, Jost LM, Taverna C, Jacky E, Honegger HP, Betticher DC, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004; 15(3): 511-6.
17. Mounier N, Gisselbrecht C. Relapses, treatments and new drugs. Best Pract Res Clin Haematol. 2012; 25(1): 49-60.
18. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007; 25(13): 1741-6.
19. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011; 25(2): 341-7.
20. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol. 2010; 28(31): 4740-6.
21. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010; 28 (12): 2085-93.
22. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013; 31(5): 573-83.
23. Haioun C, Morschhauser F, Jourdan E, Karsenti J, Hess G, Duehrsen U, et al. Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2010; 28(15s): abstr 8069.